Cytokinetics Inc (NASDAQ: CYTK) stock enjoyed a major increase of 40.4% on 9/2/25. The shares closed at $49.62. Moreover, trading volume in this advance was exceptionally high at 750% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 29.4% during the last week.
Current PriceTarget Research Rating
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment